drugset
drugset / Trial / NCT05011019

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

NCT05011019 ↗

Phase 1/2 Terminated 22 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).

Timeline

Start
2021-09-07
Primary completion
2024-02-02
Completion
2024-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AL2846 Small molecule 120 mg Oral
Subject AL2846 Small molecule 150 mg Oral

Indications

malignant peripheral nerve sheath tumor